Skip to content

Randomized controlled study on the clinical efficacy of Tiaozhi Tongmai granule in the treatment of atherosclerosis

Randomized controlled study on the clinical efficacy of Tiaozhi Tongmai granule in the treatment of atherosclerosis

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200005935
Enrollment
Unknown
Registered
2022-04-28
Start date
2022-05-20
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis

Interventions

Treatment group:Tiaozhi Tongmai granule
Control group:Tiaozhi Tongmai granule simulant

Sponsors

Fangshan Hospital Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 70 Years

Inclusion criteria

Inclusion criteria: ? Conform to the diagnostic criteria of carotid atherosclerosis; ? Conform to the standard of TCM syndrome differentiation; ? Middle aged and elderly people aged 45-70 (including 45 and 70); ? If you are taking drugs to treat carotid atherosclerosis, you need to stop the drug for more than 4 weeks; ? Sign the informed consent form (see Annex 1) and volunteer to participate in the trial;

Exclusion criteria

Exclusion criteria: ? combined serious primary diseases such as cardio cerebrovascular, liver, kidney and hematopoietic system; (2) combined type 2 diabetes mellitus with poor glycemic control and glycosylated hemoglobin (HbA1c) is more than 8%. (3)combined type I diabetes mellitus and severe endocrine diseases; ? Coagulation dysfunction, or have been using anticoagulant drugs, such as warfarin and heparin; ? Pregnant or lactating women; ? Patients with mental diseases; ? Patients with acute infectious diseases; ? Patients with malignant tumors.

Design outcomes

Primary

MeasureTime frame
Carotid ultrasound;

Secondary

MeasureTime frame
symptom score table of TCM;blood lipid;Inflammatory index;SF-36;blood sugar;

Countries

China

Contacts

Public ContactShuwen Guo
guo1163@163.com13910328362

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026